Rheumatoid Arthritis
Conditions
Keywords
tolerance, safety and pharmacokinetic characteristics
Brief summary
This study is a randomized, double-blind and placebo-controlled trial with healthy subjects. There are 6 Groups as follows: 5mg, 15mg, 30mg, 50mg, 75mg, 100mg, and each group includes12 people. A single subcutaneous injection will be administrated starting from the low dose group (in accordance with 5mg, 15mg, 30mg, 50mg, 75mg, 100mg administered subcutaneously). Pharmacokinetics and pharmacodynamics data will be collected; drug metabolism and pharmacokinetics characteristics will be analyzed. Drug safety and tolerance for subjects will be evaluated.
Detailed description
This study is a randomized, double-blind and placebo-controlled trial with healthy subjects. There are 6 Groups as follows: 5mg, 15mg, 30mg, 50mg, 75mg, 100mg, and each group includes12 people. A single subcutaneous injection will be administrated starting from the low dose group (in accordance with 5mg, 15mg, 30mg, 50mg, 75mg, 100mg administered subcutaneously). Pharmacokinetics and pharmacodynamics data will be collected; drug metabolism and pharmacokinetics characteristics will be analyzed. Drug safety and tolerance for subjects will be evaluated. The study observed blood concentrations of the experimental drug at different time points after and before administration, TNFα before and after treatment at different time points will be observed as well. C-T curve will be drawn with blood drug concentration (c) and time (T) in the trial. At the same time, the investigators will draw the average plasma concentration curve. Compartmental and non compartmental model will be used to analyze the pharmacokinetic parameters of subjects. It will be judged with linear or nonlinear elimination by the correlation analysis of AUC, Cmax of different doses. In the meantime, adverse events, vital signs, physical examination, laboratory examination and ECG will be evaluated.
Interventions
DRUGHumanized TNFα monoclonal antibody
Subcutaneous injection of different doses for healthy people Subcutaneous injection of different doses in healthy people
OTHERplacebo
Subcutaneous injection of different doses for healthy people
Sponsors
Shenyang Sunshine Pharmaceutical Co., LTD.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to 45 Years
Healthy volunteers
Yes
Inclusion criteria
1. healthy adult volunteers who are voluntary to participate in clinical trials, and signed the informed consent 2. aged 18-45 years, the same batch of subjects age difference is less than or equal to 10 years of age 3. subjects with qualified physical examination within 7 days before the trial, body mass index (BMI) from19 to 24 ,and the same batch of subjects are with the similar weight 4. the basic indicators of heart, liver, kidney and blood examination are in the normal range.
Exclusion criteria
1. subjects are during the acute or chronic infection period, or have a previous history of active tuberculosis 2. subjects are with the history of diseases of the central nervous system, cardiovascular system, kidney, liver (specific indexes of liver function), digestive system ,respiratory system or metabolic system or suffered from other significant disease 3. subjects as allergic constitution after inquiry, suspected or confirmed or have a history of drug, food allergy , or subjects with a clear history of allergies and / or allergic to the humanized TNF alpha monoclonal antibody or the ingredient of humanized TNF alpha monoclonal antibody , or serum immunoglobulin E (IgE) examination was abnormal 4. subjects are included in other clinical trials of other drugs 3 months before being enrolled in this clinical trial, or candidates used drugs known to have damage to the main organs within 3 months before this trial; 5. candidates with blood donation history 3 months before being enrolled 6. Prescription and non prescription drugs were administrated Within 2 weeks before inclusion 7. ALT or AST \> 1.5N (the upper limit of normal), Cr\>N (the upper limit of normal); 8. leukocyte absolute value less than 3.50 × 109/L or \> 9.50× 109/L, neutrophil absolute value less than 1.8× 109/L, platelet counts less than 100 × 109/L, hemoglobin is less than 100g/L 9. hepatitis B surface antigen (HbsAg), hepatitis C antibody (HCV-Ab), acquired immunodeficiency syndrome (Anti-HIV) antibody and anti Treponema pallidum antibody (TP-Ab) are positive subjects 10. candidates with positive tuberculin skin test with 5 unit dose tuberculin , the size of 48-72 hour scleroma greater than 5 mm 11. subjects with positive anti nuclear antibodies (ANA, ds-DNA, ENA) 12. subjects with positive resistantance antibody 13. subjects had a history of mental illness 14. subjects who are pregnant, lactating women or a planning pregnant within 3 months 15. subjects with the history of orthostatic hypotension 16. with drug or drug abuse history after inquiry 17. daily smoking more than 5 cigarettes or the same amount of tobacco after inquiry 18. subjects drink more than 28 units of alcohol after inquiry, or alcohol breath test are positive within 24 hours before the acceptance of the tested drugs 19. There is a family history of cancer 20. Significantly abnormal values in clinical appeared during the screening 21. subjects cannot understand, exchangeand cooperate enough, and cannot guarantee the researchers according to the scheme 22. researchers don't think it is right to participate in the research with other reasons.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Cmin | 28 days | Cmin |
| Tmax | 28 days | Tmax |
| AUC | 28 days | AUC |
| Cmax | 28 days | Cmax |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Serum creatinine and AST and ALT | 28 days | Serum creatinine and AST and ALT |
| or any other adverse events | 28 days | or any other adverse events |
Countries
China
Outcome results
None listed